Entero Healthcare Solutions LimitedENTEROCorporate

Pharmacy Retail Latest results: Jun 2026 14 quarters of data

₹1,585.00

MCap ₹6,898 Cr · P/E 41.1

Entero Healthcare Solutions Limited — Stock analysis & AI research Entero Healthcare Solutions Limited — Seasonality — best & worst months Entero Healthcare Solutions Limited — Technical indicators & charts Entero Healthcare Solutions Limited — Technical setup — score, trend, support & resistance Entero Healthcare Solutions Limited — Live exchange announcements

📋 High Sales Growth Stocks 📋 High Profit Growth Stocks 📋 Stocks With Strong Quarterly Results 📈 SuperTrend Bearish Signal

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹1,940 Cr

Sales · Jun 2026

+38.2% YoY

₹97 Cr

Operating Profit · Jun 2026

+93.7% YoY

5.0%

OPM % · Jun 2026

+38.9% YoY

₹52 Cr

Net Profit · Jun 2026

+72.2% YoY

₹8.77

EPS · Jun 2026

+37.2% YoY

📝 Entero Healthcare Solutions Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Entero Healthcare Solutions Limited reported revenue of ₹1,940 crore for the quarter ended June 2026 (Q1 FY27), up 38.2% from ₹1,404 crore in the same quarter last year, and up 1.6% sequentially over the March 2026 quarter.

Net profit rose 72.2% year-on-year to ₹52 crore, from ₹30 crore. Earnings per share (EPS) came in at ₹8.77.

Operating profit stood at ₹97 crore — an operating margin (OPM) of 5.0%, compared with 3.6% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Entero Healthcare Solutions Limited posted revenue of ₹6,592 crore, a growth of 29.4% over FY25, with a net profit of ₹146 crore (up 36.3% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹7,128 crore with a net profit of ₹168 crore.

Valuation snapshot

At the current price of ₹1,585.00, ENTERO has a market capitalisation of ₹6,898 crore and a trailing P/E of about 41.1.

Within the Pharmacy Retail industry, it is the 2nd-largest of the 2 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 52.40%, foreign institutional investors (FIIs) 4.37%, domestic institutional investors (DIIs) 15.48%, public shareholders 27.75% of Entero Healthcare Solutions Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹6,898 Cr

Current Price ?

₹1,585.0

P/E ?

41.15below ind

Industry P/E ?

43.60

P/B ?

4.08

P/S ?

0.97

P/FCF ?

237.88

Enterprise Value ?

₹7,575 Cr

EV/EBITDA ?

24.20

PEG ?

0.31

Earnings Yield ?

3.5%

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

₹7,128 Cr

OPM ?

4.4%

Profit after tax (TTM) ?

₹168 Cr

EPS (TTM) ?

₹38.52

ROCE ?

11.0%

ROE ?

9.9%

ROA ?

4.7%

Growth

Sales — latest qtr ?

₹1,940 Cr

PAT — latest qtr ?

₹52 Cr

YoY qtr sales growth ?

38.2%

YoY qtr profit growth ?

72.2%

Sales growth (3y) ?

26%

Sales growth (5y) ?

30%

Profit growth (3y) ?

131%

Profit growth (5y) ?

57%

Financial Health

Debt ?

₹677 Cr

Debt to Equity ?

0.40

Interest Coverage ?

4.1

Current Ratio ?

N/A

Ownership

Promoter holding ?

52.40%

Change in promoter holding ?

-0.02%

Pledged percentage ?

N/A

Market

Return 3 months ?

35.0%

Return 6 months ?

24.0%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	887	899	996	993	1,034	1,097	1,301	1,359	1,339	1,404	1,571	1,707	1,910	1,940	+38.2%	+1.6%
Operating Profit	20	26	29	29	29	30	42	50	49	50	62	68	86	97	+93.7%	+12.8%
Other Income	1	1	2	2	9	13	11	7	7	6	5	-4	4	3	-48.4%	-24.8%
Interest	13	14	18	16	17	10	11	10	10	11	12	14	17	21	+92.9%	+21.0%
Depreciation	7	6	6	6	7	7	7	8	8	9	10	10	15	12	+38.7%	-18.0%
Profit Before Tax	1	7	7	8	14	27	35	39	37	36	45	40	58	67	+84.6%	+15.7%
Net Profit	-4	6	5	7	21	21	26	29	31	30	37	34	45	52	+72.2%	+15.7%
EPS	-9.05	15.18	3.19	1.91	5.73	4.62	5.43	5.85	5.90	6.39	7.26	6.35	6.44	8.77	+37.2%	+36.2%
OPM %	2.3%	2.9%	2.9%	2.9%	2.8%	2.8%	3.3%	3.7%	3.7%	3.6%	4.0%	4.0%	4.5%	5.0%	+38.9%	+11.1%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY25	FY26	TTM	YoY %
Sales	₹5,096 Cr	₹6,592 Cr	₹7,128 Cr	+29.4%
Operating Profit	₹172 Cr	₹266 Cr	₹313 Cr	+55.1%
OPM %	3.37%	4.04%	4.39%	+19.9%
NPM %	2.10%	2.21%	2.35%	+5.2%
Other Income	₹39 Cr	₹11 Cr	₹8 Cr	-72.9%
Depreciation	₹30 Cr	₹44 Cr	₹47 Cr	+44.7%
Interest	₹41 Cr	₹54 Cr	₹64 Cr	+31.4%
EBIT	₹141 Cr	₹222 Cr	₹266 Cr	+57.3%
PBT	₹139 Cr	₹179 Cr	₹210 Cr	+29.2%
Tax	₹26 Cr	₹14 Cr	₹23 Cr	-44.5%
Net Profit	₹107 Cr	₹146 Cr	₹168 Cr	+36.3%
EPS	₹21.80	₹26.44	₹28.82	+21.3%
Material Cost	₹3,552 Cr	₹2,697 Cr	₹3,124 Cr	-24.1%
Employee Cost	₹147 Cr	₹117 Cr	₹129 Cr	-20.6%
Extraordinary Items	—	—	—	—

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	4	43	44	44	+0.0%
Reserves	-73	1,595	1,681	1,645	-2.1%
Borrowings	1,101	338	385	677	+75.8%
Other Liabilities	275	369	593	1,234	+108.1%
Total Liabilities	1,308	2,345	2,703	3,600	+33.2%
Fixed Assets	268	289	559	960	+71.7%
CWIP	0	0	0	0	—
Investments	0	0	58	130	+124.1%
Other Assets	1,040	2,056	2,085	2,510	+20.4%
Total Assets	1,308	2,345	2,703	3,600	+33.2%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	-45	-37	-77	96	+224.7%
Cash from Investing Activity	-49	-704	232	-303	-230.6%
Cash from Financing Activity	73	863	-74	124	+267.6%
Net Cash Flow	-21	122	82	-83	-201.2%
Free Cash Flow	-51	-41	-87	29	+133.3%
CFO/OP	-51%	-21%	-23%	36%	+256.5%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	57	57	59	67	+13.6%
Inventory Days	41	43	52	52	+0.0%
Days Payable	25	24	31	45	+45.2%
Cash Conversion Cycle	73	77	80	74	-7.5%
Working Capital Days	32	48	65	42	-35.4%
ROCE %	5%	7%	9%	11%	+22.2%

👥 Shareholding (latest 5 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	% Chg
Promoters	52.42%	52.42%	52.42%	52.42%	52.40%	-0.0%
FIIs	17.21%	14.68%	5.14%	4.03%	4.37%	+8.4%
DIIs	10.19%	9.64%	16.42%	16.62%	15.48%	-6.9%
Public	20.19%	23.26%	26.03%	26.94%	27.75%	+3.0%
No. of Shareholders	33,338	36,334	40,333	39,084	39,709	+1.6%

⚖️ Peer comparison

Industry: Pharmacy Retail · 2 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	MEDPLUS Medplus Health	₹660.00	7,926	36.0	6,892	220	8.8%	3.2%	12.3%	46.5%	23.4%	25.5%
2	ENTERO Entero Healthcare	₹1,731.80	7,537	58.8	7,128	168	4.4%	2.4%	29.4%	36.3%	38.2%	72.2%

❓ Frequently asked questions

What was Entero Healthcare Solutions Limited's revenue in Q1 FY27?

What was Entero Healthcare Solutions Limited's net profit in Q1 FY27?